Navigation Links
Signalife Wins Second Frost & Sullivan Technology Award

LOS ANGELES, March 13 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN) has received its second Frost & Sullivan Technology Award in the past three years. On March 12, 2008, at the Frost & Sullivan Awards Banquet, Signalife was awarded the Frost & Sullivan Technology Innovation Award for North American Patient Monitoring. Signalife's Chief Executive Officer, Dr. Lowell Harmison, and its inventor and Chief Scientist, Dr. Budimir Drakulic, were present to accept the award.

Signalife, Inc. is in a rare and prestigious group of companies, as a device-maker that has won the award from Frost & Sullivan two times in the past three years.

In the words of Frost & Sullivan, the Technology Award "is presented to Signalife in recognition of its superior leadership and vision in patient monitoring with its Fidelity heart monitoring systems. Signalife's unique technology provides unprecedented signal clarity in the highly sought-after real-time, wireless cardiac monitoring arena."

Frost & Sullivan continues: "Signalife strived to provide one of the most trustworthy and reliable wireless monitoring product out there, and they accomplished this by creating a technology that significantly reduced and effectively eliminated artifact noise before the ECG signal is amplified. This results in no need to filter the signal after it has been amplified preserving the entire ECG's data. Using this as the basis of all their technology, Signalife has been able to set themselves apart from other cardiac monitors. The Fidelity 100 is the first of their products, and is comprised of a wireless, real-time 12 lead ECG system ... "

Frost & Sullivan concludes: "While the Fidelity 100 product alone makes a case for product innovation, what really puts Signalife over the top is its other two products at end stage development, [including the Fidelity 200, which] is taking cardiac event monitoring to a place the industry has never been before, the over the counter, non-prescription market. As cardiac conditions continue to be the number one killer in the US, real self cardiac monitoring continues to be out of the reach of the health conscious consumer. This product works to alleviate that, by providing a credit card sized fully functional medical grade event monitor ... "

Frost & Sullivan choose Signalife -- from all others in heart monitoring - - through careful analysis that included interviews with major market participants and extensive secondary research. In accordance with Frost & Sullivan's strict policy of independence, the Company was not contacted prior to receiving notification that it was the recipient of the award.

Dr. Lowell T. Harmison -- Signalife's President and Chief Executive Officer -- commented: "I would like to personally thank Dr. Budimir Drakulic -- who I believe to be one of the most brilliant micro-electronics experts in the world -- as well as his team. It is not promotional to say that Signalife is now "over the top" in terms of giving this industry the means to change its core technology to obtain more accurate ECG's for better heart monitoring. As a result, it should alter the way heart disease is monitored, diagnosed and treated in general. Indeed, "over the top" are not my words -- they are Frost & Sullivan's. I personally look forward to unveiling a series of corporate events that will guide the profession to these solutions. Stay tuned."

Signalife will make the full Frost & Sullivan analyst report -- as well as other events surrounding the receipt of this prestigious award -- available to the public in the upcoming two weeks.

About Signalife

Signalife, Inc. is a life sciences company focused on the monitoring, detection and prevention of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices, therapies and/or technologies that simplify and reduce the costs of cardiovascular disease.

Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is Clear Data. Trusted Results.

About Frost & Sullivan

Frost & Sullivan, founded in 1961, has 26 global offices with more than 1500 industry consultants, market research analysts, technology analysts and economists. Its mission is to research and analyze new market opportunities for corporate growth. Frost & Sullivan is the world leader in growth consulting and the integrated areas of technology research, market research, economic research, corporate best practices, training, customer research, competitive intelligence and corporate strategy.

Caution Regarding Forward-Looking Statements

Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.

SOURCE Signalife, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Signalife & Athletes Foundation Dispatch Mobile Health Center to Super Bowl
2. AMEX Notifies Signalife that It Will Need to Comply with Minimum Stockholders Equity Requirement
3. Signalife Presence at XIII World Congress on Cardiac Pacing and Electrophysiology
4. U.S. Patent 7,299,083 Awarded to Signalife
5. Signalife Receives FDA Clearance for OTC Non-Prescription Event Recorder Device
6. Signalife Continues to Procure Purchase Orders, Revenues
7. NFL Hall of Fame Legend Fred Biletnikoff Joins AFL/Signalife Cardiovascular Protection Team
8. Signalife Receives Another $3.3 Million Sales Orders
9. Signalife Achieves $1.98 Million Sales Orders Thus Far
10. Signalifes Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor
11. Legendary Earvin Magic Johnson Joins AFL/Signalife Cardiovascular Protection Team
Post Your Comments:
(Date:11/25/2015)... -- 2 nouvelles études permettent d , ... entre les souches bactériennes retrouvées dans la plaque ... . Ces recherches  ouvrent une nouvelle voie ... efficace de l,un des problèmes de santé les ...    --> 2 nouvelles études permettent d ...
(Date:11/25/2015)... LOS ANGELES and HOLLISTON, Mass. ... Regenerative Technology, Inc. (Nasdaq: HART ), a biotechnology ... announced that CEO Jim McGorry will present ... Tuesday, December 1, 2015 at 2:30 p.m. PT. The ... (link below) for 30 days. Management will also be ...
(Date:11/25/2015)... 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; ... and prospects remain fundamentally strong and highlights the ... recently received DSMB recommendation to continue the ZoptEC ... of the final interim efficacy and safety data ... in men with heavily pretreated castration- and Taxane-resistant ...
(Date:11/25/2015)... Orexigen® Therapeutics, Inc. (Nasdaq: OREX ) ... chat discussion at the Piper Jaffray 27th Annual Healthcare ... discussion is scheduled for Wednesday, December 2, at 8:00 ... replay will be available for 14 days after the ... NormartVP, Corporate Communications and Business Development , BrewLife(858) 875-8629 ...
Breaking Biology Technology:
(Date:11/10/2015)... , Nov. 10, 2015 ... behavioral biometrics that helps to identify and verify ... Signature is considered as the secure and accurate ... identification of a particular individual because each individual,s ... accurate results especially when dynamic signature of an ...
(Date:11/2/2015)... MENLO PARK, Calif. , Nov. 2, 2015 /PRNewswire/ ... to $9 million to provide preclinical development services to ... Under the contract, SRI will provide scientific expertise, modern ... a wide variety of preclinical pharmacology and toxicology studies ... --> --> The PREVENT Cancer Drug ...
(Date:10/29/2015)... 2015  Rubicon Genomics, Inc., today announced an ... its DNA library preparation products, including the ThruPLEX ... Plasma-seq kit. ThruPLEX Plasma-seq has been optimized for ... libraries for liquid biopsies--the analysis of cell-free circulating ... in cancer and other conditions. Eurofins Scientific is ...
Breaking Biology News(10 mins):